InMode (NASDAQ:INMD) Issues Earnings Results

InMode (NASDAQ:INMD) posted its earnings results on Wednesday. The healthcare company reported $0.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.32 by $0.05, FiscalAI reports. The company had revenue of $92.14 million during the quarter, compared to analyst estimates of $91.58 million. InMode had a return on equity of 11.99% and a net margin of 20.69%. The company’s revenue for the quarter was down 1.1% compared to the same quarter last year. During the same period in the previous year, the company earned $0.38 EPS.

InMode Stock Up 1.8%

Shares of INMD traded up $0.24 on Wednesday, hitting $13.51. The company’s stock had a trading volume of 438,993 shares, compared to its average volume of 785,703. The firm has a market capitalization of $776.78 million, a price-to-earnings ratio of 10.97 and a beta of 1.98. The firm’s fifty day moving average price is $14.19 and its 200-day moving average price is $14.31. InMode has a fifty-two week low of $12.72 and a fifty-two week high of $16.67.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered shares of InMode from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, November 2nd. One research analyst has rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $16.00.

About InMode

InMode Ltd. is an Israel-based medical technology company that develops energy-based systems for minimally invasive aesthetic and medical procedures. Its technologies use radiofrequency energy to support treatments such as body contouring, skin tightening and facial rejuvenation, as well as certain women’s health applications. The company’s product portfolio includes platforms and handpieces such as BodyTite and FaceTite for body and facial contouring, and Morpheus8 for fractional radiofrequency skin treatments.